PANCREATIC CANCER NEWS TIPS & FEATURES


OMNI Health Media is a leading online provider of Daily Health News. OMNI’s Immunotherapy News provides summaries of developments in the prevention, screening, and management of Gastrointestinal Health Conditions as they are discovered and reported by physicians and scientists around the world. Our mission is to provide this news, including results of recent clinical trials evaluating new therapies and supportive care strategies in order to better educate patients and their caregivers, ensuring timely access to the best care available.
First Interim Analysis in SEQUOIA Phase 3 Pancreatic Cancer Study

April 18, 2018

First Interim Analysis in SEQUOIA Phase 3 Pancreatic Cancer Study

By Anonymous User anonymous_user_10987

CancerConnect News: The first interim analysis of the SEQUOIA clinical study evaluating the novel immunotherapy drug pegilodecakin in patients with pancreatic cancer will continue to enroll patients based on The Data Monitoring Committee first interim analyses and recommendation. About Pancreatic Cancer Pancreatic cancer is one of the deadliest forms of cancer. Each year, approximately 43,000 people […]

View full entry

Tags: AM0010, clinical trials, immunotherapy, Interleukin-10, News Tips and Features, News Tips and Features Other, Pancreatic Cancer, pegilodecakin, Precision Cancer Medicine, treatment


Keytruda Immunotherapy Appears Active for Treatment of Liver Cancer

February 15, 2018

Keytruda Immunotherapy Appears Active for Treatment of Liver Cancer

By Anonymous User anonymous_user_10987

CancerConnect News:  According to the results of a study presented at the recent gastrointestinal cancer symposia, Keytruda (pembrolizumab) is an active treatment for advanced liver cancer in patients who have already been treated with Nexavar (sorafenib).1 About Liver Cancer Liver cancer, or hepatocellular carcinoma (HCC), is the second most common cause of cancer-related deaths worldwide.2,3 […]

View full entry

Tags: checkpoint inhibitor, hepatocellular cancer, immunotherapy, keytruda, Liver Cancer, News Tips and Features, News Tips and Features Other, pembrolizumab, Precision Cancer Medicine


Keytruda Promising in PD-L1 Esophageal Cancer

February 13, 2018

Keytruda Promising in PD-L1 Esophageal Cancer

By Anonymous User anonymous_user_10987

CancerConnect News: The checkpoint inhibitor Keytruda (pembrolizumab) has been reported to produce an overall response rate of 30% in patients with PD-L1–positive, advanced esophageal cancer.1 About Keytruda Keytruda is a monoclonal antibody that helps to restore the body’s immune system in fighting cancer. It creates its anti-cancer effects by blocking a specific protein used by cancer […]

View full entry

Tags: checkpoint inhibitor, Esophageal Cancer, gastroesophageal junction cancer, immunotherapy, keytruda, News Tips and Features, News Tips and Features Other, pembrolizumab, Precision Cancer Medicine


Keytruda Immunotherapy Appears Promising in Advanced Gastric Cancer

September 18, 2017

Keytruda Immunotherapy Appears Promising in Advanced Gastric Cancer

By Anonymous User anonymous_user_10987

Keytruda (pembrolizumab) appears promising in patients with pretreated metastatic gastric cancer, according to late-breaking results from the KEYNOTE-059 trial presented at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid.1 Stomach cancer (gastric cancer), is the third leading cause of cancer-related deaths worldwide. Overall, the 5-year survival rate for patients with gastric cancer […]

View full entry

Tags: Gastric Cancer, immunotherapy, KEYNOTE-059 programmed death-ligand 1, keytruda, metastatic gastric cancer, News Tips and Features, News Tips and Features Other, PD-L1, pembrolizumab, Precision Cancer Medicine, stomach cancer


Clinical Data on Immunotherapy AM0010 in Advanced Pancreatic Cancer Promising

July 11, 2017

Clinical Data on Immunotherapy AM0010 in Advanced Pancreatic Cancer Promising

By Anonymous User anonymous_user_10987

ARMO BioSciences, Inc., a late-stage immuno-oncology company, announced clinical data on its lead investigational immuno-oncology drug AM0010 (pegilodecakin, PEGylated Interleukin-10) at the ESMO 19th World Congress on Gastrointestinal Cancer, taking place June 28 through July 1, 2017 in Barcelona, Spain. AM0010 is being evaluated in an ongoing Phase 1/1b clinical trial that has enrolled 352 advanced cancer patients and in a […]

View full entry

Tags: AM0010, immunotherapy, Interleukin-10, News Tips and Features, News Tips and Features Other, Pancreatic Cancer, pegilodecakin


First New Drug for Liver Cancer in a Decade: Stivarga

May 8, 2017

First New Drug for Liver Cancer in a Decade: Stivarga

By Anonymous User anonymous_user_10987

The US Food and Drug Administration (FDA) has expanded the indication for Stivarga (regorafenib) to now include treatment for patients with hepatocellular carcinoma (HCC) who have previously been treated with the drug Nexavar. Expansion of Stivarga, ‘s indication marks the first FDA-approved treatment for a liver cancer in almost a decade. Stivarga is an oral […]

View full entry

Tags: immunotherapy, Liver Cancer, News Tips and Features, News Tips and Features Other, regorafenib, Stivarga


Opdivo (nivolumab) Improves Survival in Patients with Advanced Gastric Cancer

February 6, 2017

Opdivo (nivolumab) Improves Survival in Patients with Advanced Gastric Cancer

By Anonymous User anonymous_user_10987

At the 2017 Gastrointestinal Cancers Symposium in San Francisco researchers presented new trial results demonstrating that Opdivo (nivolumab) significantly reduced the risk of death by 37% in patients with previously treated advanced gastric cancer refractory to or intolerant of standard therapy, a condition without current standard-of-care treatments. About Gastric Cancer Gastric cancer refers to cancer of the […]

View full entry

Tags: Gastric Cancer, immunotherapy, News Tips and Features, News Tips and Features Other, nivolumab, Opdivo, precision medicine


A New Drug That 'Wakes Up' Immune System Appears to Fight Pancreatic Cancer

October 4, 2016

A New Drug That ‘Wakes Up’ Immune System Appears to Fight Pancreatic Cancer

By Anonymous User anonymous_user_10987

A novel drug, IMM-101 has extended the lives of some people with metastatic pancreatic cancer and appears to have minimal side-effects. Doctors describe IMM-101 as “waking up” the immune system to attack cancer. Patients who were given the new immunotherapy drug actually felt better than those who were on standard chemotherapy, said Angus Dalgleish, professor […]

View full entry

Tags: gemcitabine, IMM-101 Gemzar, immunotherapy, News Tips and Features, News Tips and Features Other, Pancreatic Cancer


View more articles like this
More news and in-depth Pancreatic Cancer information

CONDITIONS OF THE GI TRACT